Design Therapeutics (DSGN) Competitors $3.77 +0.09 (+2.45%) As of 07/3/2025 01:01 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DSGN vs. LENZ, OCS, COGT, SNDX, CMRX, CDMO, ORIC, QURE, AVXL, and IMNMShould you be buying Design Therapeutics stock or one of its competitors? The main competitors of Design Therapeutics include LENZ Therapeutics (LENZ), Oculis (OCS), Cogent Biosciences (COGT), Syndax Pharmaceuticals (SNDX), Chimerix (CMRX), Avid Bioservices (CDMO), Oric Pharmaceuticals (ORIC), uniQure (QURE), Anavex Life Sciences (AVXL), and Immunome (IMNM). These companies are all part of the "pharmaceutical products" industry. Design Therapeutics vs. Its Competitors LENZ Therapeutics Oculis Cogent Biosciences Syndax Pharmaceuticals Chimerix Avid Bioservices Oric Pharmaceuticals uniQure Anavex Life Sciences Immunome Design Therapeutics (NASDAQ:DSGN) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations. Which has preferable earnings and valuation, DSGN or LENZ? LENZ Therapeutics is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDesign TherapeuticsN/AN/A-$49.59M-$0.99-3.81LENZ TherapeuticsN/AN/A-$49.77M-$1.77-18.38 Do analysts rate DSGN or LENZ? Design Therapeutics presently has a consensus price target of $4.00, indicating a potential upside of 6.10%. LENZ Therapeutics has a consensus price target of $46.60, indicating a potential upside of 43.23%. Given LENZ Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe LENZ Therapeutics is more favorable than Design Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Design Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00LENZ Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Do insiders and institutionals believe in DSGN or LENZ? 56.6% of Design Therapeutics shares are owned by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are owned by institutional investors. 31.2% of Design Therapeutics shares are owned by company insiders. Comparatively, 6.9% of LENZ Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media favor DSGN or LENZ? In the previous week, LENZ Therapeutics had 3 more articles in the media than Design Therapeutics. MarketBeat recorded 3 mentions for LENZ Therapeutics and 0 mentions for Design Therapeutics. LENZ Therapeutics' average media sentiment score of 0.93 beat Design Therapeutics' score of 0.00 indicating that LENZ Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Design Therapeutics Neutral LENZ Therapeutics Positive Is DSGN or LENZ more profitable? Design Therapeutics' return on equity of -22.85% beat LENZ Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Design TherapeuticsN/A -22.85% -22.02% LENZ Therapeutics N/A -23.74%-22.65% Which has more risk and volatility, DSGN or LENZ? Design Therapeutics has a beta of 1.56, meaning that its stock price is 56% more volatile than the S&P 500. Comparatively, LENZ Therapeutics has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500. SummaryDesign Therapeutics beats LENZ Therapeutics on 8 of the 14 factors compared between the two stocks. Get Design Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DSGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DSGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DSGN vs. The Competition Export to ExcelMetricDesign TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$214.02M$2.92B$5.56B$9.05BDividend YieldN/A2.44%5.24%3.99%P/E Ratio-3.8121.5627.6520.23Price / SalesN/A283.26419.56119.26Price / CashN/A41.7026.2128.59Price / Book0.887.538.035.65Net Income-$49.59M-$55.14M$3.18B$249.15M7 Day Performance5.60%4.61%2.93%3.28%1 Month Performance-5.99%0.90%1.72%3.95%1 Year Performance10.23%5.40%34.39%20.98% Design Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DSGNDesign Therapeutics0.3635 of 5 stars$3.77+2.4%$4.00+6.1%+10.2%$214.02MN/A-3.8140LENZLENZ Therapeutics1.3424 of 5 stars$30.48+1.8%$46.60+52.9%+80.2%$842.70MN/A-17.22110OCSOculis1.7287 of 5 stars$19.65+1.9%$35.33+79.8%+62.6%$841.81M$780K-7.442News CoverageCOGTCogent Biosciences2.5922 of 5 stars$7.26+0.4%$14.57+100.7%-9.8%$823.18MN/A-3.9580News CoverageAnalyst RevisionSNDXSyndax Pharmaceuticals3.1224 of 5 stars$9.19-3.1%$35.91+290.7%-55.7%$815.73M$23.68M-2.38110CMRXChimerix0.6197 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212K-9.0990CDMOAvid Bioservices0.6863 of 5 stars$12.50+0.1%$12.25-2.0%+68.4%$799.18M$139.91M-5.23320High Trading VolumeORICOric Pharmaceuticals4.2376 of 5 stars$10.00+7.4%$19.17+91.7%+40.1%$793.44MN/A-5.3580QUREuniQure2.1206 of 5 stars$13.95-1.8%$37.82+171.1%+277.2%$778.36M$27.12M-3.18500News CoverageAVXLAnavex Life Sciences3.6022 of 5 stars$9.30+2.3%$44.00+373.1%+155.8%$776.03MN/A-16.9140Positive NewsIMNMImmunome2.4317 of 5 stars$8.74-0.1%$23.33+167.0%-27.6%$761.36M$10.94M-2.7540 Related Companies and Tools Related Companies LENZ Alternatives OCS Alternatives COGT Alternatives SNDX Alternatives CMRX Alternatives CDMO Alternatives ORIC Alternatives QURE Alternatives AVXL Alternatives IMNM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DSGN) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Design Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Design Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DSGN Stock Alerts